Last reviewed · How we verify
Atropine Sulfate 0.01% Eye Drop
At a glance
| Generic name | Atropine Sulfate 0.01% Eye Drop |
|---|---|
| Sponsor | Shanghai Eye Disease Prevention and Treatment Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
- PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention (PHASE1, PHASE2)
- Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
- Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia (PHASE4)
- The Safety and Efficacy of SYD-101 in Children With Myopia (PHASE3)
- Early-Onset Myopia Intervention Project (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: